Microcystic adnexal carcinoma (MAC) is a rare and locally aggressive neoplasm that arises from the adnexal structures of the skin, such as sweat glands and hair follicles. It is characterized by infiltrative growth and has a high rate of recurrence. Our company is dedicated to advancing the understanding and research of MAC through our drug and therapy development services.
Introduction to Microcystic Adnexal Carcinoma
Microcystic adnexal carcinoma (MAC) is a malignant skin tumor that originates from the sweat glands and hair follicles. It is a rare neoplasm (about 700 cases have been documented) with distinctive histopathological features, including diffuse infiltrating syringomatous ductal differentiation. MAC is locally invasive and can extend into deep tissues such as subcutaneous fat, muscle, and even bone.
- Another Name of Microcystic Adnexal Carcinoma (MAC)
- Sclerosing sweat duct carcinoma (SSDC)
- Eccrine epithelioma
- Malignant syringoma
- Syringomatous carcinoma
- Syringoid eccrine carcinoma
- Sweat gland carcinoma with syringomatous features
Pathogenesis of Microcystic Adnexal Carcinoma
- Ultraviolet Radiation: Prolonged exposure to ultraviolet (UV) radiation, such as from excessive sunlight or tanning bed use, has been suggested as a potential risk factor for MAC.
- Prior Radiation Therapy: Patients who have received radiation therapy in the past, particularly to the head and neck region, may be at an increased risk of developing MAC.
- Immunocompromised States: Individuals with compromised immune systems, such as organ transplant recipients or those with certain autoimmune disorders, may have a higher susceptibility to MAC.
Fig. 1 Genomic changes in MACs. (Chan May P.,
et al., 2020)
Targeted Therapy of Microcystic Adnexal Carcinoma
TP53 Targeted Therapy
The TP53 gene holds significant importance in governing cell division and safeguarding against the formation of cancer cells. The identification of TP53 mutations in MCC provides compelling evidence of its implication in the development and advancement of tumors.
EGFR Targeted Therapy
The Epidermal Growth Factor Receptor (EGFR) pathway is known to be dysregulated in various cancers, including MAC. EGFR inhibitors, such as cetuximab, have shown promise in preclinical studies and clinical trials as potential targeted therapies for MAC.
PTCH1 Targeted Therapy
The PTCH1 gene is a key component of the Hedgehog signaling pathway, which plays a crucial role in cell growth and development. Aberrant activation of this pathway, often due to mutations in PTCH1, has been implicated in MAC.
IGF-1R Targeted Therapy
Insulin-like Growth Factor 1 Receptor (IGF-1R) is involved in cell proliferation and survival. Overexpression of IGF-1R has been observed in MAC, suggesting its potential as a therapeutic target. Inhibition of IGF-1R signaling may impede tumor growth and
Our Services
At our company, we are committed to advancing the field of MAC therapy through our comprehensive diagnostics and therapy development services. Our experienced team of researchers and scientists work diligently to develop novel drugs and therapies specifically tailored for MAC, focusing on the identified targets.
Therapy Development Platforms
Animal Models of Microcystic Adnexal Carcinoma
Our expertise in animal model development allows us to create reliable models that closely mimic MAC pathology, facilitating the evaluation of novel therapies in a preclinical setting.
|
Genetic Engineering Model Development |
| Our company offers cutting-edge genetic engineering model development services to create animal models that accurately represent the features of MAC. Leveraging our expertise and state-of-the-art technologies, we provide tailored solutions to address the specific research needs of our clients. |
| Optional Modifier Genes |
CACNA1S, RYR1, ATP2A1, MYLK3, Others |
| Optional Species |
Mouse, Rat, Non-human primates, Others |
Furthermore, we offer a wide range of personalized animal models tailored to meet various requirements. If you are interested in our services, please do not hesitate to contact us for further information and details regarding pricing and related services.
References
- Chan May P., et al. "Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas." Modern Pathology 33.6 (2020): 1092-1103.
- Yu Shuaixia, et al. "Four calcium signaling pathway-related genes were upregulated in microcystic adnexal carcinoma: transcriptome analysis and immunohistochemical validation." World Journal of Surgical Oncology 20.1 (2022): 142.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
